Letter: Abrupt withdrawal of antiparkinsonian drugs. 1974

P Hall

UI MeSH Term Description Entries
D009069 Movement Disorders Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions. Dyskinesia Syndromes,Etat Marbre,Status Marmoratus,Movement Disorder Syndromes,Dyskinesia Syndrome,Movement Disorder,Movement Disorder Syndrome
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson

Related Publications

P Hall
November 1974, The British journal of psychiatry : the journal of mental science,
P Hall
February 1974, The British journal of psychiatry : the journal of mental science,
P Hall
February 1983, The British journal of psychiatry : the journal of mental science,
P Hall
November 1979, The New England journal of medicine,
P Hall
January 1976, British medical journal,
P Hall
November 1975, The American journal of psychiatry,
P Hall
March 1989, La Revue du praticien,
Copied contents to your clipboard!